News | Maryland Oncology Hematology News – Maryland Oncology Hematology

Category: News

Experienced Gynecologic Oncologist Albert J. Steren, MD, FACOG, Joins Maryland Oncology Hematology

Posted on by Mark Lamplugh

Rockville, MD August 01, 2022 –( PR.com )– Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, is excited to welcome Albert J. Steren, MD, FACOG, to their team in August. With over 30 years of experience and board certified in gynecologic oncology, Dr. Steren will be seeing patients at the Aquilino Cancer Center in Rockville, located at 9905 Medical Center Drive, Suite 200, Rockville, MD, 20850.

Dr. Steren is a leader in minimally invasive gynecological surgery, and in 2008, he performed the first robotic surgery in Montgomery County. This accomplishment, as well as the rest of his distinguished career, has been recognized by numerous distinctions and awards, including being named to Newsweek’s list of top oncologists. He has also received top doctor distinctions from Washingtonian magazine, Bethesda magazine, and U.S. News & World Report.

“We are so excited to have Dr. Steren join the team at Maryland Oncology Hematology,” said Dr. George Sotos, MOH Practice President. “He has been a leading cancer surgeon in our region for decades. We are fortunate that he is bringing his skill and expertise in leading-edge treatments for gynecologic cancer to our community.”

Dr. Steren received his medical degree from George Washington University before completing his internship and residency at Johns Hopkins Hospital and his fellowship at the University of Miami Jackson Memorial Medical Center. He comes to MOH from Women’s Health Specialists of Montgomery County, where he has practiced for the past 20 years. Dr. Steren is also an associate clinical professor at Uniformed Services University of the Health Sciences, and an assistant clinical professor at George Washington University School of Medicine. “I’m thrilled to be joining the practice at the Aquilino Cancer Center,” said Dr. Steren. “I look forward to continuing my work with the community in Rockville.”

To learn more or to schedule an appointment, visit MarylandOncology.com or call 301-424-6231.

 

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,200 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

Contact Information:

Maryland Oncology Hematology

Mark W. Lamplugh Jr.

561-7629-729

Contact via Email

marylandoncology.com

Facebooktwitterlinkedinmail

Expert Care, Close to Home

Posted on by Mark Lamplugh

Maryland Oncology Hematology believes in providing patients with advanced, comprehensive cancer therapies in a community setting that allows patients to receive care near their support systems. Our highly trained and experienced physicians work closely with a talented clinical team that is sensitive to the needs of cancer patients and their caregivers. Choosing an independent practice offers patients the chance to receive compassionate, affordable cancer care that utilizes the latest technologies provided by top physicians who are experts in their field. Expert Care, Close to Home.

Patients can be assured that as an independent practice, MOH physicians are able to send patients to the best specialists or make recommendations based on specific care needs. We are never beholden to a practice or network. Unlike some of the major hospitals, our doctors are focused solely on oncology, giving patients the expert care that they deserve. At Maryland Oncology Hematology, we believe that patients are more than a number. Each patient will have a dedicated care team by their side from diagnosis through treatment to recovery.

Maryland Oncology Hematology is a community-based practice entirely owned and run by Maryland physicians. Our team is devoted to providing state-of-the-art patient care for hematology and oncology, working on behalf of our community for the benefit of patients.

Facebooktwitterlinkedinmail

George Sotos, MD, Named Practice President of Maryland Oncology Hematology

Posted on by Mark Lamplugh

Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, has elected George Sotos, MD as the new practice President.  Dr. Sotos succeeds Dr. Joseph Haggerty as of June 1 and will serve a three-year term.

Dr. Sotos practices in the Rockville Division with offices in Germantown, Bethesda, and at the Aquilino Cancer Center in Rockville.  He is board-certified in internal medicine and medical oncology.  After earning a Bachelor of Arts degree in Computer Science from Dartmouth College and a Master’s degree in Physiology from Georgetown University, he attended medical school at the Medical College of Virginia. He completed his internship and residency in internal medicine at the University of Texas Southwestern Medical Center/Parkland Memorial Hospital, and his fellowship in medical oncology at the National Institutes of Health.  Dr. Sotos has been actively involved at Suburban Hospital serving as chair of the hematology and oncology subsection for 22 years, on the medical executive committee for 12 years, and as the coordinator of the neuro/aerodigestive, gastrointestinal and genitourinary multidisciplinary tumor boards for 11 years.  Most recently, he served on the MOH Board from 2018 to 2022, and as the Managing Partner of the Rockville Division from 2019 to 2022.

Dr. Sotos was named a Top Doctor by Bethesda Magazine in 2021 and 2019, and consistently by the Washingtonian over the last twenty years. He is affiliated with the American College of Physicians, Montgomery County Medical Society, Medical and Chirurgical Faculty of the State of Maryland, American Society of Clinical Oncology, and the American Medical Association.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care.  MOH provides expertise in medical oncology and hematology, surgery for breast, colorectal and gynecologic malignancies, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs.  MOH takes pride in providing state-of-the-art cancer therapies in a community setting, close to patients’ homes and support systems.  Our physicians are supported by a talented clinical and administrative team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com. 

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,200 dedicated, independent physicians nationally who share resources and expertise to deliver integrated care and better outcomes to patients — close to home. The Network is supported by McKesson Corporation whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices.  Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

Media Inquiries

Maryland Oncology Hematology
Mark W. Lamplugh Jr.
561-7629-729
marylandoncology.com
Facebooktwitterlinkedinmail

Experienced Hematologist and Medical Oncologist Harminder Sethi, MD joins Maryland Oncology Hematology

Posted on by Mark Lamplugh

Dr. Sethi has over 18 years of experience, specializing in targeted and biological therapy.

Maryland, 3/24/2022 – Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, has added Harminder Sethi, MD, to their hematology and medical oncology team. Dr. Sethi specializes in treatment plans that include targeted and biological therapy designed to treat the unique intricacies of each patient’s illness. “Dr. Sethi will see patients at the Hyattsville office located at 6505 Belcrest Rd, Hyattsville, MD 20782, as well as the White Oak Cancer Center at 11886 Healing Way Suite 701, Silver Spring, MD, 20904 once a week. Upon its opening, he will also see patients at the DC office located at 1140 Vamum St. NE in Washington, DC.

Dr. Sethi completed his initial medical education in India before finishing his residency at North Shore University Hospital, NY followed by a fellowship in oncology/hematology at Medstar Washington Hospital Center. During his fellowship, Dr. Sethi completed bone marrow transplant training in affiliation with the Fred Hutchinson Cancer Center in Seattle, WA, and additional oncology training with the National Heart, Blood, and Lung Institute. Dr. Sethi has ardent respect for his patients and develops treatment plans that include targeted therapy and biological therapy based on the most up-to-date national guidelines tailored to each patient’s particular circumstances and goals.

“I’m thrilled to join the team at Maryland Oncology Hematology to serve patients throughout our community,” said Dr. Sethi, hematology and medical oncologist, MOH. “Through our access to the latest technology and groundbreaking treatments, I’m happy to bring patients new hope in fighting cancer.”

“Dr. Sethi is an excellent addition to MOH,” said Joseph Haggerty, MOH Practice President. “His impressive experience in both hematology and medical oncology will provide a great benefit to the local community.”

 

To learn more or to schedule an appointment, visit MarylandOncology.com or call (301) 779-8800.

 

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,400 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

Facebooktwitterlinkedinmail

Maryland Oncology Hematology Adds Experienced Gynecologic Surgical Oncologist James Barter, MD, FACOG to White Oak Cancer Center

Posted on by Mark Lamplugh

Dr. Barter is an accomplished surgeon and clinical researcher who will provide state-of-the-art treatments and minimally invasive surgical options to patients in the region.

Maryland, 3/15.2022 – Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, has added Dr. James Barter, MD, FACOG to their gynecologic oncology and surgical team at White Oak Cancer Center. Dr. Barter is experienced in minimally invasive surgeries and has performed more than 1,700 robotic surgeries and procedures.

Dr. Barter joins Maryland Oncology Hematology at The White Oak Cancer Center. Dr. Barters’ current interests include surgery using the Da Vincia surgical robot to assist in gynecologic surgery. He is ranked in the top 15 users worldwide for robotic gynecologic and gynecologic oncology procedures and has lectured both locally and internationally on the topic. Along with his extensive research with Dr. David Min and the HCSS research division, Dr. Barter has activated and overseen clinical trials with over 1,300 patients entered in protocols since 2006.

“I’m looking forward to partnering with Maryland Oncology Hematology to provide leading-edge, research–based, and patient-centered care to the community,” said Dr. Barter, a gynecologic surgeon at White Oak Cancer Center. “With a firm understanding of the latest treatment advances and surgical techniques, I hope to bring patients new cancer care options.”

Dr. Barter is recognized as one of the country’s leading gynecologists by Good Housekeeping, perennially as one of the Top Doctors in the Washington, D.C. area, as well as one of only two gynecologic oncologists noted as top doctors in Northern Virginia. He is currently a clinical professor at George Washington University and director of gynecologic oncology research at Holy Cross Hospital. He received his medical degree from the University of Virginia and completed two years of internal medicine and four years of obstetrics and gynecology at Duke University Medical Center, followed by a fellowship in gynecologic oncology at the University of Alabama Medical Center. He was at Lombardi Cancer Center/ Georgetown University Medical Center for 16 years, rising to the rank of professor.

His four-year interest in the development of a serum blood test for ovarian cancer detection will soon culminate in published research involving serum proteomics. In conjunction with Holy Cross, Dr. Barter continues his interest in protocols dealing with novel approaches for ovarian cancer treatment, having received research grants.

“We’re thrilled to have Dr. Barter join our team of talented surgeons at Maryland Oncology Hematology” said Kashif Firozvi, MD, Director at White Oak Cancer Center. “His background in research and clinical trials, as well as his impressive experience in both gynecologic oncology and surgery will be of great benefits to the local community.”

White Oak Cancer Center is located at 11886 Healing Way Suite 101, Silver Spring, MD, 20904. To learn more or to schedule an appointment, visit MarylandOncology.com or call 301.343.3892.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,400 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Maryland Oncology Hematology also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

To be distributed to local media:

Practice: Maryland Oncology Hematology

Contact: Mark Lamplugh

Phone : 561-762-9729

Email : mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

2022 DC ScopeItOut 5K for colorectal cancer alliance

Posted on by Mark Lamplugh

Join Colorectal Cancer Alliance at Freedom Plaza on March 27, 2022, to run or walk the DC ScopeItOut 5K. Register today, fundraise and build your team, and get ready to run during colorectal cancer awareness month. For those not able or not yet comfortable being in person, run in your own neighborhood as a virtual ScopeItOut Coast to Coast runner.

Link to Register: https://impact.ccalliance.org/event/2022-dc-scopeitout-5k/e364416https://lnkd.in/dPWn-grw

Facebooktwitterlinkedinmail

White Oak Welcomes Gynecological Oncologist & Surgeon James F. Barter, MD, FACOG on 4/1/2022

Posted on by Mark Lamplugh

Dr. Barter is recognized as one of the country’s leading gynecologists by Good Housekeeping, perennially as one of the Top Doctors in the Washington, D.C. area, as well as one of only two Gynecologic Oncologists noted as top doctors in Northern Virginia. He is currently a Clinical Professor at George Washington University and director of Gynecologic Oncology research at Holy Cross Hospital. He received his medical degree from the University of Virginia and completed two years of Internal Medicine and four years of Obstetrics and Gynecology at Duke University Medical Center, followed by a fellowship in Gynecologic Oncology at the University of Alabama Medical Center. He was then at Lombardi Cancer Center / Georgetown University Medical Center for 16 years, rising to the rank of Professor. Dr. Barter joined Maryland Oncology Hematology in April 2022 at White Oak Cancer Center.  Dr. Barters’ current interests include surgery using the Da Vincia surgical robot to assist in Gynecologic surgery.

He has lectured locally and internationally on this topic. He was recently ranked in the top 15 users worldwide for robotic gynecologic and gynecologic oncology procedures and is presenting the Holy Cross Gynecologic and Gynecologic Oncology experience at the Middle Atlantic Gynecologic Oncology Symposium. His four-year interest in the development of a serum blood test for Ovarian Cancer detection will soon culminate in published research involving Serum Proteomics. In conjunction with Holy Cross, he continues his interest in protocols dealing with novel approaches for Ovarian Cancer treatment, having received research grants. A novel study to determine cancer cell sensitivity to chemotherapy has just begun.

Dr. Barter begins seeing patients at the White Oak Medical Center on 4/1/2022.

Facebooktwitterlinkedinmail

Talking Cancer Prevention on Great Day Washington

Posted on by Mark Lamplugh

Watch Nicholas DeMonaco, M.D on the WUSA9 talk show Great Day Washington talking about cancer prevention.

Facebooktwitterlinkedinmail

Fox 5 DC – Cancer: Fight over Fear Pt. 1

Posted on by Mark Lamplugh

Watch FOX 5 DC reporter Ayesha Khan as she shares her fight with breast cancer at the Shady Grove Adventist HealthCare Aquilino Cancer Center. This is the first in a series of segments with Colette Magnant, MD, FACS. We want to thank Ayesha for sharing her ongoing experience with breast cancer.

Facebooktwitterlinkedinmail

Maryland Oncology Hematology Announces Carolyn Hendricks, MD, FASCO Has Been Named to the Board of The American Society of Clinical Oncology

Posted on by Mark Lamplugh

The ASCO’s Board of Directors is comprised of oncology leaders who are elected to positions reflecting various specialties within the oncology field.

Bethesda, MD (January 2022) — Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, announced today that medical oncologist Carolyn Hendricks, MD, FASCO has been named to the Board of The American Society of Clinical Oncology. Dr. Hendricks was elected to the Designated Community Oncologist seat and will begin a four-year term starting in June 2022.

Dr. Hendricks is a medical oncologist specializing in breast cancer genetics, screening, and treatment at Maryland Oncology Hematology. She has served on a number of ASCO committees, including as chair of the ABIM-ASCO Breast Cancer Exam Subcommittee, chair-elect of the Practice Quality Improvement Steering Group, past chair of the Government Relations Committee, and a member of Clinical Practice Committee and the Quality Training Program Steering Group, among another volunteer service. Dr. Hendricks was honored as Advocate of the Year by the Association for Clinical Oncology in 2019.

Dr. Hendricks specializes in breast cancer and is an active member of a multidisciplinary team focused on breast cancer genetics, screening, and treatment. She provides leading-edge and comprehensive treatment at the local level. Praised for her involvement in clinical trials for breast cancer, she brings knowledge and support to community groups by providing education about breast cancer.

Her greatest accomplishments include her ASCO (American Society of Clinical Oncology) volunteer activities both nationally and internationally in the area of quality cancer care. She received the prestigious ASCO Fellowship Award in June 2018. Dr. Hendricks is also known for heightening breast cancer awareness and delivering quality breast cancer care throughout her career.

“We are thrilled to congratulate Dr. Hendricks on this incredible achievement,” said Joseph M. Haggerty, M.D, Practice President at Maryland Oncology Hematology. “With her focus on promising new advancements in breast cancer treatment and her commitment to providing education throughout the community, Dr. Hendricks is integral in delivering comprehensive and expert care to our breast patients.”

Dr. Hendricks is currently seeing patients at MOH’s Bethesda location. Immediate appointments are available for newly referred patients to provide a high level of support and prompt access to care. Please call 301.424.6231 to make an appointment.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The  US Oncology Network (The Network). This collaboration unites the practice with more than 1,380 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. MOH also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

To be distributed to local media:
Practice: Maryland Oncology Hematology
Contact: Mark Lamplugh
Phone: 561-762-9729
Email: mark.lamplugh@usoncology.com

Facebooktwitterlinkedinmail

Kashif Firozvi, M.D. was a guest on Great Day Washington

Posted on by Mark Lamplugh

Kashif Firozvi, M.D. was a guest on Great Day Washington to talk about the White Oak Cancer Center.

Visit our other guest spots for Great Day Washington https://www.wusa9.com/search?q=%22Maryland+Oncology+Hematology%22

 

Facebooktwitterlinkedinmail

Health Insurance Update

Posted on by Mark Lamplugh

It’s Open Enrollment time! Please make sure your Maryland Oncology Hematology team is aware of any changes to your medical insurance so that we can avoid delays in your care.

 

We are here to support you as you make choices or changes, whether is due to Medicare or Medicaid plans revisions, a new job with new insurance coverage, or other updates in your coverage. It is very important that you share any insurance coverage updates with the care team at your clinic so that we can plan ahead for any administrative requirements to continue your care.

 

Your Patient Benefits Representative will update your coverage in our system to ensure a smooth transition. This is critical, as many of the treatments you receive require prior authorization from the insurance company. Providing the team with your new insurance information gives us a head start on authorizing your care for the coming year, which will help prevent delays.

 

No change in your coverage is too small,  please share them all – Including, but not limited to: moving from one Medicare replacement plan to another, moving from Traditional Medicare to a replacement plan, change in commercial plans,  changes in the ID number, and/or group number,  or changes in your name or employer.

 

Thank you for trusting Maryland Oncology Hematology team with your care.

Facebooktwitterlinkedinmail

Covid-19 Update

Posted on by Mark Lamplugh

As we move into the heart of the holiday season, I know many of you are seeing the dramatic increase of COVID cases across Maryland and the U.S.  Throughout the pandemic, we’ve adjusted our policies to ensure the continued safety of our patients and staff, and we are now implementing some changes to promote the health and safety of our patients, staff, and community.

Effective Monday, December 27, all MOH practices will:

  • Implement a NO VISITOR policy.  Caregivers will only be provided access if the following criteria are met by the patient:
    • Wheelchair-bound requiring assistance.
    • Cognitive dysfunction.
    • Translator needed.
  • Leverage telemedicine visits as much as possible.

Thank you for your continued commitment as we work to keep each other, our patients, and our communities safe.  Warmest wishes for a healthy and happy holiday season.

Facebooktwitterlinkedinmail

Maryland Oncology Hematology is a guest on Great Day Washington

Posted on by Mark Lamplugh

Dr. Surupa Sen Gupta and Dr. Colette Magnant represented Maryland Oncology Hematology on Great Day Washington to explain the importance of screenings, self-exams, and living a healthy lifestyle for breast cancer awareness month.

 

Facebooktwitterlinkedinmail

Stop Breast Cancer For Life

Posted on by Mark Lamplugh

As we approach breast cancer awareness month tomorrow Maryland Oncology Hematology is proud to be partnering with Lifetime and The Breast Cancer Research Foundation for their 27th year of “Stop Breast Cancer for Life.”

Our lives have changed, but what hasn’t is our fight against breast cancer. Lifetime has proudly supported breast cancer research for over 25 years. Get information on mammograms during COVID-19, read personal breast cancer stories, watch thriver videos, find resources, and more with our features below. Link: https://www.mylifetime.com/stop-breast-cancer-for-life

 

 

Facebooktwitterlinkedinmail

Do I need to get a COVID-19 vaccine booster?

Posted on by Mark Lamplugh

As of Friday August 13th, the CDC is now recommending that people with moderate to severe compromised immune systems should receive an additional dose (booster) of the COVID-19 vaccine after the initial two-dose vaccine series. At MOH, many of our patients have moderately to severely compromised immune systems and do not always build the same level of immunity compared to people with normal immune systems.  The CDC recommendation identifies people with a range of conditions including:

  • Those receiving active cancer treatment for tumors or cancers of the blood
  • Those that have had a bone marrow or stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
  • Those with advanced or untreated HIV infection
  • Those actively being treated with high-dose corticosteroids or other drugs that may suppress your immune response

 

A full list of conditions can be found on CDC’s website.

 

Frequently Asked Questions (FAQs)

 

  1. Can you mix and match the vaccine type?

For people who received either Pfizer or Moderna’s COVID-19 vaccine series, a 3rd dose of the SAME mRNA vaccine should be used at least 4 weeks after completing the two-dose vaccine series.   A person should not receive more than three mRNA vaccine doses.

 

  1. What should immunocompromised people who received the J&J vaccine do?

The FDA’s & CDC’s recent amendment only applies to mRNA COVID-19 vaccines from Pfizer and Moderna.  There is not enough data at this time to determine whether immunocompromised people who received the J&J vaccine also have an improved antibody response following an additional dose of the same vaccine.

 

  1. Do I need a letter from my doctor in order to get the vaccine? 

At this time you do not need a letter from your physician in order to get the COVID-19 booster.  You will be able to self-attest that you meet criteria.

 

  1. If I am immunocompromised and I get the booster, can I stop wearing a mask?

While the Delta variant is surging, an additional vaccine dose for some people with weakened immune systems could help prevent serious and possibly life-threatening COVID-19 cases within this population.  Even after vaccination, people who are immunocompromised should continue follow current prevention measures (including wearing a mask, staying 6 feet apart from others they do not live with, and avoiding crowds and poorly ventilated indoor spaces) to protect themselves and those around them against COVID-19 until advised by your provider .

Facebooktwitterlinkedinmail

Maryland Oncology Hematology Gives New Meaning to Personalized Cancer Care

Posted on by Mark Lamplugh

A Partnership Between Physicians and Their Community

Maryland Oncology Hematology believes in providing patients with advanced, comprehensive cancer therapies in a community setting that allows patients to receive care near their support systems. Our highly trained and experienced physicians work closely with a talented clinical team that is sensitive to the needs of cancer patients and their caregivers. Choosing an independent practice offers patients the chance to receive compassionate, affordable cancer care that utilizes the latest technologies provided by top physicians who are experts in their field. The best of care, close to home.

Patients can be assured that as an independent practice, MOH physicians are able to send patients to the best specialists or make recommendations based on specific care needs. We are never beholden to a practice or network. Unlike some of the major hospitals, our doctors are focused solely on oncology, giving patients the expert care that they deserve. At Maryland Oncology Hematology, we believe that patients are more than a number. Each patient will have a dedicated care team by their side from diagnosis through treatment to recovery.

Maryland Oncology Hematology is a community-based practice, entirely owned and run by Maryland physicians. Our team is devoted to providing state-of-the-art patient care for hematology and oncology, working on behalf of our community for the benefit of patients.

 “I’m excited to be part of this highly respected community-based private practice,” said Jason Taksey MD., medical oncologist and managing partner for new Annapolis location. “Maryland Oncology Hematology delivers state-of-the-art care and remarkable treatments in an outpatient center that is safe, modern, convenient, and responsive to patient feedback.”

Why Patients Trust MOH

  • Comprehensive care including new radiation oncology services offered at White Oak Cancer Center in Silver Spring
  • Top-Rated Breast and Colorectal Surgeons
  • Team of almost 50 physicians and more than 50 years of experience
  • Research and phase 1-3 drug trial participation
  • Convenient locations
  • Financial guidance
  • Support groups and education
  • Hospital affiliations

Choosing an Independent Cancer Provider

As an independent practice, Maryland Oncology Hematology is proud to offer patients increased access to integrated, evidence-based cancer care and clinical research throughout the communities of Maryland. When compared to oncology services at big hospitals, independent cancer centers are typically more conveniently located, more individualized, and more likely to offer all necessary services under one roof. Independent cancer centers are also more cost effective for patients.

At MOH, our state-of-the-art infusion centers offer a full range of chemotherapy services, laboratory testing, clinical trials, and support services, provided by people who have an unwavering commitment to achieving the best possible result.

Our providers also have the freedom to choose the best possible specialists and hospital services for our patients, as well as arranging referrals for additional consultation or specialty care when needed. We ensure that our patients receive the best care based on each person’s unique diagnosis and treatment needs.

Maryland Oncology Hematology is able to offer cutting edge and innovative clinical research trials without the delays that many hospitals face. In partnership with US Oncology Network, MOH is able to unite the practice with more than 1,380 independent physicians dedicated to delivering value-based, integrated care to patients. These independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes.

Benefits to Patients

At Maryland Oncology Hematology, we strive to help patients through positive patient-doctor relationships while utilizing the latest in advanced technology. Other benefits include:

Better Access and Convenience

Community facilities offer integrated care close to home meaning there is less travel for patients. This provides reduced ER visits, admissions, and overnight hospital stays because of the proximity to care. At community cancer care clinics, patients receive treatments from one care team. In the hospital setting, patients are likely to see a different doctor and nurse throughout treatment.

Personalized Medicine

Our team utilizes a multidisciplinary approach to cancer care, combined with the most advanced treatments, cutting-edge technologies, and clinical trials research program. This includes precision medicine based on the genetic profile of a patient or their specific diseases. Molecular testing can be used to help target cancer treatments, as well as improve accuracy of a diagnosis in complex cases or help patients learn if there is a risk of cancer that runs in their families.

Immediate Appointments

At Maryland Oncology Hematology, we offer immediate appointments to newly referred patients, ensuring they get the care they need without stressful and unnecessary delays they might otherwise experience in major hospital systems. Our team will schedule a consult with one of our experts who can provide guidance and treatment options, as well as address any patient and family member concerns.

Community care offers patients:

  • Shorter wait times
  • Easily accessible surface parking and patient drop-offs
  • Less likelihood of catching infection associated with hospital visits
  • Access to support services, including social workers, financial assistance, and reimbursement specialists
  • Access to groundbreaking clinical trials
  • Lower cost of care across all cancer types when compared to hospital settings[1]

“We’re grateful to have the privilege to bring remarkable cancer care advances to our patients, as well as offer therapies that can improve their quality of life,” said Dr. Jason Taksey. “At MOH Annapolis, we are excited to offer superior care options for our patients and our surrounding community.”

 

About Maryland Oncology Hematology

 

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland with locations in Annapolis, Bethesda, Brandywine, Clinton, Columbia, Frederick, Germantown, Lanham, Laurel, Mt. Airy, Rockville and the White Oak Cancer Center in Silver Spring. Our more than 40 physicians are devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. For more information, visit MarylandOncology.com.

 

Media Contact

Company Name: Maryland Oncology Hematology

Contact Person: Mark W Lamplugh Jr

Email: Send Email

Phone: 5617629729

Country: United States

Website: https://mdoncology.wpengine.com

 

[1] https://ascopost.com/News/59474

Facebooktwitterlinkedinmail

Maryland Oncology Hematology Welcomes Colette Magnant, MD, FACS to Their Expanding Breast Surgical Oncology Team

Posted on by Mark Lamplugh

Dr. Magnant joins Dr. Surupa Sen Gupta at their Rockville Division to offer the community advanced surgical care with the latest breast preservation techniques.

Maryland Oncology Hematology  (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, is proud to announce that Dr. Colette Magnant, MD, FACS is joining its Rockville division.

Dr. Magnant has been treating breast cancer for over 34 years and has established herself as one of the premier breast cancer surgeons in the Washington, D.C. metropolitan area.  With her extensive training and wealth of experience, she provides her patients with a superior understanding of breast cancer biology, as well as compassionate state of the art breast preservation procedures, and advanced surgical techniques. She will be joining Dr. Surupa Sen Gupta to expand our breast surgical oncology services at our Rockville division, and together they, along with our expert and experienced medical oncologists, will anchor our comprehensive breast cancer program in the Rockville division.

‘We’re thrilled to welcome Dr. Magnant  to our experienced breast surgical team. Her stellar reputation as a top breast surgeon is well-deserved and we are fortunate that she has decided to bring her skills to our practice and to our community.  She shares our vision of providing state-of-the-art multidisciplinary cancer care, and we are delighted to have her join in our expansion said George Sotos MD, Managing Partner, Rockville Division. ‘With her focus and strong surgical experience in breast cancer treatment, Dr. Magnant is a welcome addition to our team as we dedicate our practice to delivering the very best in comprehensive and integrated care to our breast cancer patients.

Dr. Magnant is board certified in general surgery, specializing in advanced breast surgery techniques, including skin and nipple-sparing mastectomies and minimally invasive breast conserving surgeries. After earning her medical degree from the Medical College of Virginia in Richmond, Dr. Magnant completed her general surgery internship at Indiana University Medical Center and her residency at Georgetown University Hospital in Washington, DC. She is most recently the past director of the Sullivan Center for Breast Health at Sibley Hospital, as well as an assistant professor at John Hopkins University. In addition to teaching, Dr. Magnant has made numerous media appearances and delivered dozens of university lectures.

‘I’m proud to work alongside the dynamic team at Maryland Oncology Hematology, said Dr. Magnant. ‘We’re dedicated to delivering compassionate and comprehensive breast health services to the surrounding community, allowing our patients to receive the best of care, close to home.

Dr. Magnant will be joining Dr. Sen Gupta who is board certified in general surgery, fellowship trained in breast surgical oncology, and specializes in minimally invasive breast-conserving surgeries.

Dr. Magnant will start seeing patients at MOH’s Rockville office on April 1st. Appointments are available for newly referred patients to provide a high level of support and easy access to care. Please call 301.424.6231 to make an appointment.

About Maryland Oncology Hematology

Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.

About US Oncology Network

Maryland Oncology Hematology is a practice in The US Oncology Network  (The Network). This collaboration unites the practice with more than 1,380 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation , whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. MOH also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.

 

Media Contact
Company Name: Maryland Oncology Hematology
Contact Person: Mark W Lamplugh Jr
Email: Send Email
Phone: 5617629729
Country: United States
Website: https://mdoncology.wpengine.com

 

Facebooktwitterlinkedinmail

What are Complementary Therapies, and What Can They Do for Cancer Patients?

Posted on by Mark Lamplugh

Complementary therapies are products and/or practices that differ from standard medical care provided by your oncologists. These non-traditional methods are in no way meant to replace cancer treatment. They’re called complementary because they are meant to work alongside your cancer treatment in hopes of relieving symptoms and side effects, relieving pain, and improving quality of life.

Complementary therapies typically concentrate on relaxation and reducing stress. Many of these types of therapies may help calm emotions, relieve anxiety, reduce nausea, minimize pain, provide extra energy, and increase overall health and well being.

Many cancer patients feel as though complementary therapies leave them with a little more control over their health as they go through cancer treatment. They also tend to appreciate that complementary therapies do not require additional medicines. When the symptoms and side effects of your cancer treatment are difficult to cope with, these alternative approaches can be supportive in bringing relief. Before adding any complementary therapy to your current treatment, however, it is important to talk with your cancer specialist.

There are many different types of complementary therapy. Be sure to tell your therapist or instructor that you are a cancer patient before you start any complementary therapy. This is important information that could impact what they recommend for you.

Complementary therapies include, but are not limited to:

  • Aromatherapy and Essential Oils: The use of essential oils either by inhalation or topical application. Oils can aid in reducing anxiety, nausea, depression, and pain. Be sure you receive instruction before applying any oils to your skin.
  • Acupuncture: The practice of applying needles, heat, pressure, and other treatments to one or more places on the skin known as acupuncture points. It can be effective for cancer treatment side effects such as nausea and vomiting, pain, and fatigue.
  • Chiropractic: A chiropractor can provide hands-on manipulation of the spine (adjustment) that can help with stresses cancer treatment has put on the musculoskeletal system, which can increase mobility, flexibility, strength, and function. It may also help relieve nausea, fatigue, headaches, and other body pains in the back and neck area.
  • Herbal supplements: May help strengthen the immune system and ease the side effects of cancer treatment. These can interact with medicines being used for cancer treatment and should always be discussed with your cancer care team before using.
  • Massage therapy: A hands-on method of manipulating the soft tissues of the body that can promote relaxation and help with pain, fatigue, immune function.
  • Guided Imagery (Visualization): A technique that focuses and directs the imagination toward a specific goal. Practicing this may be able to reduce feelings of depression and increase feelings of well-being. The University of Michigan provides a free guided imagery audio library.
  • Art or music therapy: Creative arts that promote a better quality of life by aiding in the reduction of depression, anxiety, and pain. It can also be a positive outlet for emotional expression.
  • Yoga: Yoga connects the mind and body through movement and meditation. Yoga can help improve quality of life by relieving both physical and emotional stress.
  • Support groups: Group meetings can help cancer patients cope. Having emotional support can help improve both quality of life and survival.

In most cases, cancer doctors are very supportive of their patients using complementary therapies. This is typically because they have seen people cope better with the cancer and its treatment.

Again, it isn’t recommended that complementary therapies replace cancer treatment. They are simply meant to be used in conjunction with the current cancer treatment. Talking with your cancer specialist can help find the right balance between the complementary therapies and traditional treatments you are receiving for your cancer. Our oncologist at Maryland Oncology Hematology are able to talk you through these complementary cancer therapies, as well as additional methods of therapy that may be best for your cancer care. If you are in Maryland or the Washington D.C. area, you can schedule a consultation by picking the Maryland Oncology Hematology location that’s most convenient to you and calling to make an appointment.

Sources:

Facebooktwitterlinkedinmail

Weather Update 2/19/2021

Posted on by Mark Lamplugh

Check our 2/19/2021 weather update page for practice closures and operating hour changes for tomorrow. All recent updates will be added or changed as offices make decisions. If your office isn’t listed, then no changes have be made yet. Feel free to call your office with any questions regarding appointments. Check this page for updates throughout the evening and tomorrow.

Columbia office will be open normal business hours. 

Capital division which includes Silver Spring White Oak Cancer Center & Laurel will be open normal hours.

Our Southern division which includes Brandywine & Lanham will be open 1 hour late on 2/19/2021

Our Frederick division which included our Frederick & Mt Airy office will open at 10AM 2/19/2021

Rockville Division which includes Rockville – Aquilino Cancer Center, Germantown and Bethesda will be open at 10AM on  2/19/2021

 

Annapolis will open at 10AM on 2/19/2021 due to the weather.

Facebooktwitterlinkedinmail

Weather Update 2/2/2021

Posted on by Mark Lamplugh

Due to weather our Frederick & Mt Airy offices will be opening 10AM on 2/2/2021. If you have questions regarding rescheduling, you can reach our Frederick office at 301-695-6777 and Mt Airy at 301-829-0707.

Mt Airy: https://mdoncology.wpengine.com/locations…/locations/mt-airy/

Frederick: https://mdoncology.wpengine.com/locatio…/locations/frederick/

Due to weather our Columbia office will be opening at 10:00AM with 2Hr delay. If you have questions regarding rescheduling, you can reach our Columbia office at 410-964-2212

Columbia: Columbia | Maryland Oncology Hematology

 

Due to weather our Rockville, Germantown and Bethesda offices will be opening 2 hr delay on 2/2/2021. If you have questions regarding rescheduling, please call your office at  301-424-6231

Rockville: Rockville – Aquilino Cancer Center | Maryland Oncology Hematology

Bethesda: Bethesda | Maryland Oncology Hematology

Germantown: Germantown | Maryland Oncology Hematology

All other offices are operating as usual.

Facebooktwitterlinkedinmail

Linda M. Burrell, M.D. Announces Retirement January 29, 2021

Posted on by Mark Lamplugh

Maryland Oncology Hematology is sad to announce that Dr. Linda Burrell will be retiring from practice effective January 29, 2021.   Dr. Burrell has been a pillar of our organization and has provided exceptional patient care to our community for over three decades.  Her clinical excellence and fierce dedication to her patients has established her as one of the leading physicians in our region with Dr. Burrell being recognized as a Top Doctor by Washingtonian Magazine.  More importantly, as you will often hear from her patients, she has set the benchmark for what it means to offer compassionate care in the most difficult of times.

We at Maryland Oncology Hematology will always value Dr. Burrell for her many contributions to our organization. Her hard work, commitment and dedication set an example for all of those around her. While we will miss her greatly, we know that she will continue to be an example we can all follow in both our professional and personal lives. She has made each of us better as individuals and our organization is now a better place because she was a part of it.  She is an irreplaceable member of our team and we all thank her for her years of service.

All of us at Maryland Oncology Hematology look forward to continuing the incredible legacy Dr. Burrell has established in our community. For her existing patients, Dr. Burrell will be coordinating transition of your care.  For her referring physicians, our group will be happy to provide care for your new patient referrals.  Our entire team of physicians and administrators are ready to assist in any way possible and to answer any questions you may have.

Please join us as we celebrate Dr. Burrell and her many accomplishments and wish her well as she begins this next chapter!

 

Thank You,

The Maryland Oncology Hematology Team

Facebooktwitterlinkedinmail

COVID-19 Vaccines for Patients Frequently Asked Questions* (FAQ)

Posted on by Mark Lamplugh

 Q – Which vaccines are available?

  • At this time, two vaccines have been submitted for United States Food and Drug (FDA) Emergency Use Authorization (EUA).
  • Vaccine availability in Maryland will depend on a number of factors including availability as well as vaccine storage capabilities.
  • General information published about each vaccine includes:
    • The Pfizer-BioNTech vaccine: Contains a tiny fragment of the virus’s genetic code made in the lab – called messenger RNA, or mRNA – that codes for a part of the virus called the ‘spike protein’, which sits on the outside of the virus. When the mRNA is injected into the body it can instruct cells to produce these proteins, priming the immune system to be able to recognize and destroy the coronavirus, without exposing the body to the virus itself. This vaccine must be stored at -70°C (-94 oF). This vaccine received FDA EUA approval on December 11, 2020.
  • Moderna vaccine: Like the Pfizer-BioNTech vaccine, the Moderna vaccine contains mRNA that codes for the virus’s spike protein. It can be stored at –20°C

(-4oF; normal freezer temperature) for up to 6 months. This vaccine received FDA EUA approval on December 17, 2020.

 

Q – Which vaccine is most appropriate for me?

  • All the vaccines that are approved by the FDA may be considered.

 

Q – Is the vaccine effective against COVID-19?

  • Detailed information about the effectiveness of each vaccine is available from the respective manufacturers, the FDA and the CDC. Based on clinical trials reviewed by the FDA:
  • The Pfizer vaccine is 95% effective 7 days from the 2nd dose.
  • The Moderna vaccine is 94.5% effective 14 days from the 2nd dose
  • Ongoing studies to assess how well the vaccine works in real-world conditions will continue.

 

Q – How do we know the vaccine is safe?

  • FDA EUA approval requires the same rigorous review of clinical trial data as any other FDA approval.

 

Q – Is the vaccine safe if I am receiving immunotherapy?

  • Based on information studying the influenza vaccines, it appears that vaccines are safe to use in this population of patients. Further information on the COVID-19 vaccines, is not available currently.
  • We will continue to monitor for information and guidance on immunization in special populations including patients on immunotherapy.

Q – Has it been studied/is it safe in immunocompromised individuals? What about in pregnancy and children?

  • The EUA for the Pfizer-BioNTech vaccine is for ages 16 and older.
  • There is no published data in the studies on this; however, we will continue to monitor for published guidance.
  • There have been no published studies to include pregnant women or children <12 yrs. of age. These data points are still being collected.

 

Q – What are the common side effects?

  • Each vaccine manufacturer has identified various possible side effects for its respective vaccine. Information about side effects is available from each manufacturer, but some reported side effects include:
  • Pfizer-BioNTech vaccine
    • Fatigue 3.8%
    • Headache 2.0%
    • Older adults demonstrated fewer side effects
  • Moderna vaccine
    • Injection site pain 2.7%
    • Fatigue 9.7%
    • Myalgia (muscle aches and pains) 8.9%
    • Arthralgia (joint pain) 5.2%
    • Headache 4.5%
    • Pain 4.1%
    • Erythema (superficial redness of the skin) 2.0%

 

Q – Will vaccination help or hinder my response to treatment?

  • There is no published data in the studies on this; however, the decision to receive the vaccine should be made after consultation with your health care provider.

 

Q – What happens if I refuse to receive the vaccine?

  • You as a patient always have the right to refuse any treatment. Your provider should provide adequate education to ensure you can make an informed decision.

 

Q – How soon after I get the vaccine will I become protected from contracting COVID-19?

  • According to the manufacturer, the Pfizer vaccine provides optimal immunity 7 days after the second dose.
  • According to the manufacturer, the Moderna provides optimal immunity 14 days after the second dose.
  • Other COVID-19 precautions such as mask wearing, hand washing, and social distancing should be continued after vaccination. It has not been clearly established at what point after vaccination it is safe to discontinue other COVID-19 precautions.

 

Q – Can I get COVID-19 from getting the vaccine?

  • Per the CDC you cannot develop COVID-19 from vaccines that do not use the live virus.
  • There are several different types of vaccines in development. The goal for each of them is to teach our immune systems how to recognize and fight the virus that causes COVID-19. Sometimes this process can cause symptoms, such as fever. These symptoms are normal and are a sign that the body is building immunity.

 

 

 

*These FAQs consolidate into one document information published or otherwise provided by the Centers for Disease Control, the World Health Organization, the US Food and Drug Administration, professional societies, academic centers, and other experts. Any recommended courses of action made by the foregoing agencies or experts and included in this document are only recommendations.

 

 

 

 

 

 

Facebooktwitterlinkedinmail

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology